Gilead Sciences: GILD should be taking a very strong look at Hep B
RBC thinks GILD should be taking a strong look at Hep B and these assets aren't expensive and they could be consolidating or buying assets. Firm highlights some public plays, noting they're mostly RNAi plays knocking down S-antigen. But they think public companies such as ARWR still remain attractive -- Phase II data will be most important to the firm in 2015-16. They note TKMR will go into Phase I in 2015, ISIS is in Phase I with an S-antigen antisense drug and could have data soon (haven't heard any update, partnered with GSK). They note ALNY will be in Phase I in 2016.